BioSpace News Archive

Nuvo Pharmaceuticals Inc. announced that its wholly owned subsidiary, Aralez Pharmaceuticals Canada Inc. has received a Notice of Compliance from Health Canada for Suvexx™.

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2019.

iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today that it has enrolled the first patient in its Phase 1/2 study with EOS884448 (EOS-448), the company’s investigational ADCC-enabled antagonist anti-TIGIT antibody drug candidate.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), today presented at the American Academy of Pain Medicine’s 36th Annual Meeting.

Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced the pricing of the Company’s previously announced underwritten public offering of 18,333,334 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase an aggregate of 18,333,334 shares of common stock, at a combined effective public offering price of $0.30 per share of common stock

NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced that management will present at the Cowen 40th Annual Healthcare Conference at The Boston Marriott Copley Place in Boston on Tuesday, March 3, 2020 at 9:20 a.m. ET/6:20 a.m. PT..

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its fourth quarter and full year ended December 31, 2019.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment of Dr. Olivier Brandicourt to its Board of Directors effective March 2, 2020. Dr. Brandicourt served as Chief Executive Officer and a member of the Board of Directors of Sanofi from 2015 to 2019

Illumina, Inc. announced that it has filed a patent infringement suit relating to BGI’s “CoolMPS” sequencing products.

Biogen Inc. and Sangamo Therapeutics, Inc. announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.